LUCA Biologics is a biotech startup that focuses on developing living medicines to target the vaginal microbiome for urogenital and reproductive health. The company's work is based on the research of Dr. Jacques Ravel and is aimed at addressing health issues that affect a significant portion of the global female population, such as urinary tract infections (UTIs), bacterial vaginosis (BV), and pregnancy complications.

The vaginal microbiome, which is the community of microorganisms living in the vagina, plays a crucial role in maintaining health. LUCA Biologics aims to modulate this microbiome through microbiota-based therapeutics, which can protect, restore, and sustain the healthy function of this ecosystem. This approach has the potential to transform how diseases are prevented and treated.

LUCA Biologics operates in the biotech market, serving clients who are in need of innovative solutions for urogenital and reproductive health issues. The company's business model revolves around the discovery and development of live biotherapeutics. It has a proprietary platform for this purpose, and a library of over 1,000 strains of vaginal microbiota, assembled over 15 years of research.

The company makes money by developing and selling these therapeutics. Given the large number of women affected by the health issues LUCA Biologics is targeting, there is a significant potential market for its products.

Keywords: Biotech, Living Medicines, Vaginal Microbiome, Urogenital Health, Reproductive Health, Microbiota-based Therapeutics, Biotherapeutics, Urinary Tract Infections, Bacterial Vaginosis, Pregnancy Complications.